It's FDA-approved, it targets visceral belly fat specifically, and it works completely differently from GLP-1 drugs. Here's the plain-English version of what tesamorelin actually does.
Research context only. This page is for educational purposes based on published data. Tesamorelin is FDA-approved only for HIV-associated lipodystrophy. All other use is off-label. This is not medical advice.
Tesamorelin is a synthetic version of a hormone your body already makes called Growth Hormone Releasing Hormone — GHRH for short. Its job is simple: it tells your pituitary gland to release growth hormone (GH). That's it. It doesn't inject GH directly into you. It nudges your own body to produce more of it naturally.
You may have heard of it as Egrifta — that's the brand name under which it's FDA-approved for treating excess visceral fat in HIV patients. It's the only GHRH peptide with an actual FDA approval, which gives it a more robust clinical evidence base than most research peptides.
The key distinction: Tesamorelin is not growth hormone. It's the signal that tells your body to make growth hormone. This matters because it preserves your body's natural feedback loop — when enough GH is present, the system self-regulates and slows down. That's fundamentally different from injecting exogenous GH, which bypasses that safety mechanism entirely.
Outside of its FDA-approved use, tesamorelin is widely studied by researchers interested in body composition, visceral fat reduction, and cognitive function in aging populations.
Your brain runs a hormonal axis that controls growth hormone. Think of it as a chain of command:
Normally, your hypothalamus releases GHRH in pulses — particularly during deep sleep and after exercise. This is the natural trigger for GH release.
GHRH binds to receptors in your pituitary gland, which responds by releasing a pulse of growth hormone into your bloodstream.
Tesamorelin is a stabilized analog of GHRH — it binds the same pituitary receptors and triggers the same GH pulse. Because it mirrors the natural signal, the body's feedback system (somatostatin) still functions normally to prevent excess GH buildup.
The released GH stimulates IGF-1 production in the liver, which is responsible for most of GH's effects on body composition — fat mobilization, lean mass preservation, and metabolic rate support.
Why the pulsatile pattern matters: Natural GH release happens in pulses, not a constant stream. Tesamorelin maintains this pulsatile pattern. Synthetic GH injections don't — they create a sustained elevation that suppresses your body's own production over time. This is why many researchers and clinicians view GHRH peptides as a more physiologically appropriate approach.
This is tesamorelin's headline result — and it's well-documented. Visceral fat is the deep abdominal fat that wraps around your organs. It's different from subcutaneous fat (the kind you can pinch). Visceral fat is more metabolically active, more inflammatory, and more strongly linked to cardiovascular disease, insulin resistance, and metabolic syndrome.
Tesamorelin preferentially targets visceral fat while preserving lean mass — a distinction most fat loss interventions can't claim
Most interventions — diet, exercise, even GLP-1 drugs — reduce overall body fat, but they don't specifically target visceral fat. Tesamorelin is notable because its mechanism appears to preferentially mobilize visceral adipose tissue.
The Phase 3 trials leading to FDA approval used MRI and CT scanning to precisely measure visceral adipose tissue (VAT) before and after treatment. Participants using tesamorelin saw roughly 15% reductions in VAT over 26 weeks, compared to minimal change in placebo groups.
Secondary findings also showed improvements in waist circumference, triglyceride levels, and body image scores. Lean mass was largely preserved, which is significant — most pure caloric restriction reduces both fat and muscle simultaneously.
Important nuance: The FDA trial population was HIV patients with lipodystrophy — a condition that causes abnormal fat redistribution. The applicability to general population visceral fat reduction is supported by the mechanism but hasn't been studied in the same controlled Phase 3 format. Off-label research use draws on this data plus smaller studies in non-HIV populations.
Tesamorelin has FDA approval as Egrifta (and later Egrifta SV) for a specific indication: reducing excess visceral fat in HIV-positive adults with lipodystrophy. That's a narrow approval but it's real, and it matters for a few reasons.
The FDA-approved clinical dose is 2mg once daily via subcutaneous injection. This is also the most commonly referenced dose in off-label research contexts. Some researchers use 1mg daily, particularly when stacking with other compounds or during a longer cycle.
Timing note: Insulin blunts GH release significantly. Injecting tesamorelin after a meal — especially a carbohydrate-heavy one — can reduce efficacy. The fasted bedtime window works with your body's natural overnight GH pulse rather than against it.
Tesamorelin has a reasonably well-characterized safety profile from its clinical trials — better documented than most research peptides precisely because it went through FDA approval. That said, side effects exist and are worth understanding.
Who should avoid it: Active malignancy (GH can stimulate tumor growth), hypopituitarism requiring other hormone replacement, or known hypersensitivity to the compound. The clinical trial exclusion criteria are the clearest guide — always discuss with a physician who knows your history.
No — it's a GHRH analog that signals your pituitary to produce GH. The distinction matters: your body's feedback systems stay intact, your own production isn't suppressed, and the GH release remains pulsatile and physiological rather than constant and supraphysiological.
The approval is for a specific population with a specific condition. It means the compound is well-studied and has a defined safety profile — but the trials were in HIV lipodystrophy patients, not the general population. Off-label use draws on that data, but the indication doesn't transfer automatically.
Tesamorelin's primary documented effect is visceral fat reduction, with lean mass preservation as a secondary benefit. It's not an anabolic compound in the traditional sense. It won't produce dramatic muscle gains — that's not its mechanism or its clinical track record.
Clinical data shows visceral fat levels begin returning toward baseline after discontinuation — similar to what's seen with GLP-1 drugs. The compound manages the condition while it's being used. Maintenance or repeat cycles are the more realistic long-term approach.
Current vendor pricing with promo codes, reconstitution guide, and dosage protocol in one place.